QA1.791 Billable / specific Familial cancer syndrome with pathogenic BRCA2 mutation

ICD-10-CM QA1.791 identifies “Familial cancer syndrome with pathogenic BRCA2 mutation” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.

Chapter 17: Congenital malformations, deformations, chromosomal abnormalities, and genetic disorders

Exempt from present-on-admission reporting

Code-level instructions

Inclusion terms2
  • BRCA2-cancer predisposition syndrome
  • Hereditary breast and ovarian cancer syndrome with pathogenic BRCA2 mutation

Inherited instructions

Chapters 17 · Congenital malformations, deformations, chromosomal abnormalities, and genetic disorders (Q00-QA1)

Excludes 21

inborn errors of metabolism (E70-E88)

Note1

Codes from this chapter are not for use on maternal records

QA1 · Genetic disorders associated with neoplasms, not elsewhere classified

Excludes 21

multiple endocrine neoplasia [MEN] syndromes (E31.2-)

Code also4
  • , if applicable, any associated conditions, such as:
  • genetic susceptibility to malignant neoplasm by site (Z15.0-)
  • malignant neoplasms (C00.0-C96.9)
  • personal history of malignant neoplasm (Z85.-)
Official index references

Official index references (3)

Syndrome (3)

Official conversion history

Historical assignments from the CDC conversion table support data retrieval. They do not authorize substituting a previous code for the current code.

Release dates 2026-10-01

Previous assignment: Z15.09

History

Code history

Latest recorded change · FY2027

ChangedUnchanged
FY2027Selected edition

Effective from

  • Added

Familial cancer syndrome with pathogenic BRCA2 mutation

Billable diagnosis code

CDC/NCHS · FY2027

All editions (1)

All editionsEffective fromCode history
FY20272026-10-01Added

This entry is a complete code in the selected edition. Reference checks do not establish clinical appropriateness or guarantee reimbursement.